Aspen continues anesthetic buying spree with GSK deal
South African generic drugs maker Aspen Pharmacare Holdings Inc. on Monday, Sept. 12, agreed to buy Glaxosmithkline plc's (GSK) anesthesia portfolio in a deal that could be worth £280 million ($371.6 million).
The acquisitive South African company will pay £180 million for products including Ultiva, Nimbex, Tracrium, Mivacron and Anectinein. It also agreed to make up to £100 million in milestone payments.
London-based GSK, who had previously sold off the U.S. and Canadian rights t...